Longboard Pharmaceuticals Competitors and Similar CompaniesClear all
Longboard Pharmaceuticals's competitors and similar companies include Autolus, Aurealis Therapeutics, ADMA Biologics and Batavia Biosciences.
 Longboard Pharmaceuticals Longboard Pharmaceuticals, Inc. (Longboard) is a biopharmaceutical company focused on developing transformative medicines for neurological diseases. |  Autolus Autolus Therapeutics is a private biopharmaceutical company, focused on the development and commercialization of engineered T-cell immunotherapy products. |  Aurealis Therapeutics Aurealis Therapeutics (formerly known as Aurealis Pharma) is a biopharmaceutical company developing medicines for the treatment of cancer and chronic wounds. |  ADMA Biologics ADMA Biologics develops plasma-based biologics for the treatment and prevention of certain infectious diseases. |  Batavia Biosciences Batavia Biosciences is a biotechnology company providing biopharmaceuticals for proof-of-concept and clinical studies, as well as aid product development for all major classes of biopharmaceuticals. | |
Founding Date | Founding Date 2020 | Founding Date 2014 | Founding Date 2010 | Founding Date 2004 | Founding Date 2010 |
Type | Type Public | Type Public | Type Private | Type Public | Type Private |
Tags | |||||
Locations | Locations San Diego, US HQ San Diego, US | Locations London, GB HQ London, GB | Locations Basel, CH HQ Kuopio, FI | Locations Ramsey, US HQ Boca Raton, US | Locations Leiden, NL HQ Hong Kong, HK Woburn, US |
Employees | Employees 5056% increase | Employees 647 | Employees 18 | Employees 313 | Employees 153 |
Valuation ($) | Valuation ($) 2.3 b | Valuation ($) 1.2 b | Valuation ($) N/A | Valuation ($) 3.9 b | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $75.4m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $510.2m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $86.6m (FY, 2025) | Cost of goods N/A | Cost of goods $217.4m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit ($10.7m) (FY, 2025) | Gross profit N/A | Gross profit $292.8m (FY, 2025) | Gross profit N/A |
Net income | Net income ($54.4m) (FY, 2023) | Net income ($287.5m) (FY, 2025) | Net income N/A | Net income $146.9m (FY, 2025) | Net income N/A |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 5.7m (almost 9 years ago) | Latest funding round N/A | Latest funding round $ 8m (almost 10 years ago) |
Total funding raised | Total funding raised $ 56m | Total funding raised $ 281.7m | Total funding raised $ 5.7m | Total funding raised $ 20m | Total funding raised $ 8m |
For sources of this data, please see the company profile
View Company Profiles
Autolus
HQ
London, GB
Employees
647
Autolus Therapeutics is a private biopharmaceutical company, focused on the development and commercialization of engineered T-cell immunotherapy products.
View companyAurealis Therapeutics
HQ
Basel, CH
Employees
18
Aurealis Therapeutics (formerly known as Aurealis Pharma) is a biopharmaceutical company developing medicines for the treatment of cancer and chronic wounds.
View companyADMA Biologics
HQ
Ramsey, US
Employees
313
ADMA Biologics develops plasma-based biologics for the treatment and prevention of certain infectious diseases.
View companyBatavia Biosciences
HQ
Leiden, NL
Employees
153
Batavia Biosciences is a biotechnology company providing biopharmaceuticals for proof-of-concept and clinical studies, as well as aid product development for all major classes of biopharmaceuticals.
View company